Market Overview

UPDATE: Valeant Posts Upbeat Q4 Profit

Related VRX
Bill Ackman: I'd Support Mike Bloomberg For President, GE Isn't Cheap Enough And 'Lots Of New Stuff' On Herbalife
Valeant Pharmaceuticals Gets Antitrust OK For Synergetics USA Deal
Bulls Rally, But Bears Lurk (Seeking Alpha)

Valeant Pharmaceuticals International (NYSE: VRX) posted a profit in the fourth quarter.

Valeant posted its quarterly net income of $123.8 million, or $0.36 per share, versus a year-ago loss of $89.1 million, or $0.29 per share. Excluding one-time items, it earned $2.15 per share.

Its revenue jumped to $2.06 billion. However, analysts were projecting a profit of $2.06 per share on revenue of $2.06 billion.

Valeant shares gained 1.94% to $149.14 in pre-market trading.

Posted-In: profitEarnings News


Related Articles (VRX)

Get Benzinga's Newsletters